KA/EN
Register
Medicines reference
Search
Search
Active substance

Betaine

Favourites

Methyl donor. Not applicable (not a medicine). Forms: tablet.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Betaine
Georgian name
ბეტაინი
Authorisation status
Complementary feed / supplement
Not a medicine and not required to be authorised as one - it is sold under feed law.
Registered in Georgia
0 of 1 forms
Products
Hepatiale Forte Advanced
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Hepatiale Forte Advanced, Tablet

tablet, VetExpert
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy
5.3/10
Weak evidence support
vetman assessment

Hepatiale Forte Advanced

tablet, VetExpert
Assessed clinical scopeDog · Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy · By mouth
Care settingVeterinarian-directed outpatient adjunct with exact-form dose review, concurrent-product screening and objective reassessment.
vetman score 5.3/10 Weak evidence support
Evidence confidence: Low Georgia: Not a medicine · Verified on 22 Oct 2026

The strongest Hepatiale record because an exact-product dog pilot exists, but its uncontrolled sponsor-linked biomarker result and schedule mismatch still leave overall value weak.

Regulatory and scientific credibility5.0/10

Exact transparent composition and a current peer-reviewed exact-product pilot improve traceability, but complementary-feed oversight, open-label design and manufacturer conflicts leave credibility moderate.

Clinical efficacy4.5/10

The 17-dog open-label pilot found improved liver biomarkers after eight weeks, but no control, small heterogeneous sample, sponsor involvement and no patient-centred or durable outcomes prevent a causal efficacy claim.

Safety and tolerability6.0/10

Seventeen dogs completed eight weeks without reported adverse effects, supporting short-term tolerability only; no controlled frequency estimate, long-term, reproductive or severe-disease safety is available.

Clinical practicality6.0/10

Oral administration is manageable, but the every-other-day to daily transition at 10 kg and mismatch between the current low-weight label and the pilot regimen require careful schedule selection.

Full-course cost-effectiveness-

No verified current Georgian patient-adjusted course price or evidence-based treatment duration is available, so cost is excluded.

Important safety and use flags

  • Complementary feed, not a medicine. Medicine-authorisation status is not applicable; this category neither proves nor disproves clinical efficacy.
  • Adjunct only after diagnosis and disease-specific care. Do not substitute this product for indicated diet, antidote, antimicrobial, immunosuppression, copper management, biliary intervention or other treatment.
  • The exact Advanced dog study was open-label, uncontrolled, small and manufacturer-linked, and measured mainly biomarkers. It does not prove regeneration, fibrosis reversal, survival benefit or durable disease control.
  • Do not transfer efficacy, safety or dose from another Hepatiale presentation, another phospholipid/silymarin formulation, human studies or intravenous studies.
  • The 2026 dog pilot used one tablet/10 kg daily, while the current page gives animals up to 10 kg one tablet every other day. Do not claim that the trial validates the current low-weight or feline schedule.
  • Biochemical improvement is not equivalent to a patient-centred outcome. Define the intended clinical objective and a reassessment/stop point before starting.
  • No regulator-grade adverse-event frequency or contraindication section is available. Review soy sensitivity, GI tolerance, age, severe organ disease and every concurrent medicine or supplement; Advanced also contains milk thistle and zinc.
  • Avoid duplicate hepatoprotective ingredients and review polypharmacy. Native extracts and multi-ingredient products are not automatically interchangeable, and interaction magnitude is not established for the exact product.
  • Monitor the diagnosed disease objectively with clinical status, appetite, weight and condition-appropriate liver biochemistry, imaging or histology. Stop or revise the plan if no defined benefit appears or disease progresses.
  • Exact safety in pregnancy, lactation, breeding animals, neonates and long-term severe hepatic, renal or multisystem disease is not established; use only after explicit individual benefit-risk review.
Assessment sources
  1. VetExpert Advanced2026
  2. Advanced canine pilot2026
  3. ACVIM canine hepatitis consensus2019
  4. Canine liver nutraceutical review2013
  5. Dog-cat hepatic supplement review2020
  6. Veterinary cytoprotectant review2009
  7. Canine GBM hepatoprotectant trial2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy
4.3/10
Weak evidence support
vetman assessment

Hepatiale Forte Advanced

tablet, VetExpert
Assessed clinical scopeCat · Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy · By mouth
Care settingVeterinarian-directed outpatient adjunct with exact-form dose review, concurrent-product screening and objective reassessment.
vetman score 4.3/10 Weak evidence support
Evidence confidence: Low Georgia: Not a medicine · Verified on 22 Oct 2026

A transparent complementary feed with workable label administration but no exact feline outcome evidence; use only as a monitored adjunct, not a treatment substitute.

Regulatory and scientific credibility4.5/10

Exact composition and category are transparent, but the only exact-product peer-reviewed trial is canine, open-label and manufacturer-linked; no feline dossier or trial supports the assessed species.

Clinical efficacy3.0/10

Advanced has a small positive dog pilot but no feline outcome study; canine biomarkers and ingredient mechanisms do not validate the current feline schedule or clinical benefit.

Safety and tolerability4.5/10

No exact feline target-animal safety study or adverse-event frequency is available. Manufacturer silence cannot prove safety; soy, GI tolerance, concurrent supplements and product-specific ingredients require review.

Clinical practicality5.5/10

A whole tablet every other day avoids fractional dosing for cats up to 10 kg, but no schedule exists above that boundary and the canine daily pilot does not validate feline administration.

Full-course cost-effectiveness-

No verified current Georgian patient-adjusted course price or evidence-based treatment duration is available, so cost is excluded.

Important safety and use flags

  • Complementary feed, not a medicine. Medicine-authorisation status is not applicable; this category neither proves nor disproves clinical efficacy.
  • Adjunct only after diagnosis and disease-specific care. Do not substitute this product for indicated diet, antidote, antimicrobial, immunosuppression, copper management, biliary intervention or other treatment.
  • The exact Advanced dog study was open-label, uncontrolled, small and manufacturer-linked, and measured mainly biomarkers. It does not prove regeneration, fibrosis reversal, survival benefit or durable disease control.
  • Do not transfer efficacy, safety or dose from another Hepatiale presentation, another phospholipid/silymarin formulation, human studies or intravenous studies.
  • The 2026 dog pilot used one tablet/10 kg daily, while the current page gives animals up to 10 kg one tablet every other day. Do not claim that the trial validates the current low-weight or feline schedule.
  • No exact-product feline clinical outcome study was located. Canine biomarker results and ingredient mechanisms cannot establish feline benefit or target-animal safety.
  • No regulator-grade adverse-event frequency or contraindication section is available. Review soy sensitivity, GI tolerance, age, severe organ disease and every concurrent medicine or supplement; Advanced also contains milk thistle and zinc.
  • Avoid duplicate hepatoprotective ingredients and review polypharmacy. Native extracts and multi-ingredient products are not automatically interchangeable, and interaction magnitude is not established for the exact product.
  • Monitor the diagnosed disease objectively with clinical status, appetite, weight and condition-appropriate liver biochemistry, imaging or histology. Stop or revise the plan if no defined benefit appears or disease progresses.
  • Exact safety in pregnancy, lactation, breeding animals, neonates and long-term severe hepatic, renal or multisystem disease is not established; use only after explicit individual benefit-risk review.
Assessment sources
  1. VetExpert Advanced2026
  2. Dog-cat hepatic supplement review2020
  3. Veterinary cytoprotectant review2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
L-Arginine75 mg L-Glutamine75 mg Soy Phospholipids70 mg Betaine70 mg Silymarin50 mg Zinc Oxide0.4 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Vet Planet Sp. z o.o. (VetExpert) · Poland
Registration
Georgia Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 EU Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 UK Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 US Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Current manufacturer schedule: cats and dogs up to 10 kg, one tablet every other day; dogs over 10 kg, one tablet per 10 kg once daily. The 2026 dog pilot used one tablet per 10 kg daily, so its results do not directly validate the current low-weight or feline schedule.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗